{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:08:58Z","timestamp":1784146138808,"version":"3.55.0"},"reference-count":51,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) with\n                      <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                      alterations treated with palbociclib are reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Eligible patients had advanced OC, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with\n                      <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                      alterations, and no remaining standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+). Simon two-stage design with a null DC rate of 15% versus 35% (power = 0.85; \u03b1 = .10) was used. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Twenty-eight patients were enrolled from February 2017 to April 2023, and all had OC with a\n                      <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                      alteration (loss [n = 21], mutation [n = 5], and loss and mutation [n = 2]). One patient was not evaluable for efficacy because of an excluded genomic finding. Three patients had a partial response and seven had SD16+ for DC and OR rates of 38% (90% CI, 25 to 100) and 11% (95% CI, 2 to 29), respectively. The null hypothesis of 15% DC rate was rejected (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .004). The median PFS was 8 weeks (95% CI, 8 to 18) and the median OS was 33 weeks (95% CI, 24 to 73). Nineteen patients (68%) had at least one treatment-related grade 3-4 adverse event (AE) or serious AE including anemia, dyspnea, fatigue, leukopenia, neutropenia, and thrombocytopenia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Palbociclib met the prespecified criteria to declare a signal of activity in patients with OC and\n                      <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                      alterations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00456","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:59:11Z","timestamp":1784145551000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Palbociclib in Patients With Ovarian Cancer With\n                    <i>CDKN2A<\/i>\n                    Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study"],"prefix":"10.1200","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02693535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dan S.","family":"Veljovich","sequence":"first","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein M.","family":"Ali-Ahmad","sequence":"additional","affiliation":[{"name":"Michigan Cancer Research Consortium, Lansing, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-165X","authenticated-orcid":true,"given":"R. Wendel","family":"Naumann","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Sutter Cancer Research Consortium, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1018-519X","authenticated-orcid":true,"given":"Andrew","family":"Gregory","sequence":"additional","affiliation":[{"name":"Advocate Aurora Healthcare, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[{"name":"City of Hope Chicago, Zion, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamidele","family":"Adesunloye","sequence":"additional","affiliation":[{"name":"City of Hope Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Arend","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bell","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-1495","authenticated-orcid":true,"given":"Marina","family":"Frimer","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwell Health, Northwell Health Cancer Institute, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-2471","authenticated-orcid":true,"given":"Bernard","family":"Tawfik","sequence":"additional","affiliation":[{"name":"University of New Mexico Comprehensive Cancer Center, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-9924","authenticated-orcid":true,"given":"Ramya","family":"Thota","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, Murray, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":true,"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-6742","authenticated-orcid":true,"given":"Pam K.","family":"Mangat","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1535235"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.10.011"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00791-5"},{"key":"e_1_3_11_5_2","article-title":"Palbociclib in patients with Non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with Non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/po.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_6_2","article-title":"Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Worden FP","unstructured":"Worden FP, Pisick E, Rothe M, et al: Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/po-24-00477","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8077"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01661-8"},{"key":"e_1_3_11_9_2","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E, et al: Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/po.19.00124","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0036"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34649"},{"key":"e_1_3_11_12_2","article-title":"Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry study","author":"Schuetze S","unstructured":"Schuetze S, Rothe M, Mangat PK, et al: Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.24.00219","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100626"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101697"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1685291"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.05.022"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01348"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102028"},{"key":"e_1_3_11_19_2","article-title":"Tissue\/site-agnostic study of ribociclib for tumors with cyclin D-CDK4\/6 pathway genomic alterations: A phase II, open-label, single-arm basket study","author":"Peguero J","unstructured":"Peguero J, Sohal DPS, O\u2019Neil BH, et al: Tissue\/site-agnostic study of ribociclib for tumors with cyclin D-CDK4\/6 pathway genomic alterations: A phase II, open-label, single-arm basket study. JCO Precis Oncol 10.1200\/po.18.00383","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_20_2","article-title":"Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_11_24_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_25_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_26_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_27_2","first-page":"JCO2300702","article-title":"Pembrolizumab in patients with tumors with high tumor mutational burden: Results from the targeted agent and profiling utilization registry study","volume":"10","author":"Duvivier HL","year":"2023","unstructured":"Duvivier HL, Rothe M, Mangat PK, et al: Pembrolizumab in patients with tumors with high tumor mutational burden: Results from the targeted agent and profiling utilization registry study. J Clin Oncol 10:JCO2300702, 2023","journal-title":"J Clin Oncol"},{"key":"e_1_3_11_28_2","article-title":"Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study","author":"Meric-Bernstam F","unstructured":"Meric-Bernstam F, Rothe M, Mangat PK, et al: Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00385","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_29_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_30_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_31_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_32_2","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Sahai V","unstructured":"Sahai V, Rothe M, Mangat PK, et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00527","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_11_34_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104545"},{"key":"e_1_3_11_36_2","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00609","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_37_2","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry study","author":"Ganti AK","unstructured":"Ganti AK, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00041","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_38_2","article-title":"Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Rothe M, Mangat PK, et al: Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO-25-00649","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_39_2","article-title":"Olaparib in patients with solid tumors with ATM alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Carrizosa DR","unstructured":"Carrizosa DR, Rothe M, Mangat PK, et al: Olaparib in patients with solid tumors with ATM alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/po-25-00716","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_11_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_11_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0229-0"},{"key":"e_1_3_11_43_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0681"},{"key":"e_1_3_11_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2150"},{"key":"e_1_3_11_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.006"},{"key":"e_1_3_11_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.109"},{"key":"e_1_3_11_47_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2270"},{"key":"e_1_3_11_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv120.01"},{"key":"e_1_3_11_49_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2955"},{"key":"e_1_3_11_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos114"},{"key":"e_1_3_11_51_2","article-title":"Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer","author":"Asghar US","unstructured":"Asghar US, Kanani R, Roylance R, et al: Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer. JCO Precis Oncol 10.1200\/po.21.00002","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00819-1"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:59:21Z","timestamp":1784145561000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1200\/PO-26-00456"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00456","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600456"}}